Exploration of Stem Cells in the Treatment of Diabetes
DOI:
https://doi.org/10.54097/1h9tvg28Keywords:
Stem Cells, mesenchymal Stem Cells, diabetes, treatment.Abstract
Stem cell therapy for diabetes is moving from basic research to clinical validation, bringing new hope for a curative strategy. This article systematically reviews the core progress and challenges in this field. Diabetes is fundamentally characterized by the failure of pancreatic β-cell function, and current therapies cannot reverse the disease course. Stem cells, due to their self-renewal and differentiation potential, have become a key candidate for replacing damaged β-cells. Embryonic stem cells and induced pluripotent stem cells can generate insulin-secreting cells through directed the differentiation, among which the embryonic stem cell route has entered clinical trials and has obtained evidence of functional cure; induced pluripotent stem cells are suitable for individualized treatment, but are hindered by safety and efficiency issues. Mesenchymal stem cells improve the pancreatic microenvironment through immunomodulation and paracrine effects. Multiple meta-analyses have shown that they can significantly reduce glycated hemoglobin and reduce insulin dosage and have good safety. In 2026, a Chinese team reported a study on regenerating islets, which was the first to achieve islet function reconstruction in humans and obtained approval for new drug clinical trials in China and the United States, marking a key step in clinical transformation. However, immune rejection, tumor risk, production standardization, and insufficient long-term efficacy evidence remain major obstacles. In the future, it is necessary to leverage gene editing, metabolic reprogramming, and multi-omics technologies to promote the implementation of individualized and standardized treatment plans and ultimately achieve functional cure of the diabetes.
Downloads
References
[1] Zhang Sijie, Lu Fangzhou, Fu Qi, et al. Research Progress on Stem Cell Therapy for Reconstructing Pancreatic Islet Function [J]. Chinese Journal of Endocrinology and Metabolism, 2025, 41(10): 878-882.
[2] Kruzshak S, Williams FG, Camci-Unal G, Tzanakakis ES. Engineering the oxygen microenvironment for pancreatic islet transplants. NPJ Regen Med. 2026 May 20. DOI: https://doi.org/10.1038/s41536-026-00479-6
[3] Fujikura J, Anazawa T, Toyoda T, Ito R, Kimura Y, Yabe D. Toward a cure for diabetes: iPSC and ESC-derived islet cell transplantation trials. J Diabetes Investig. 2025 Mar;16(3):384-388. DOI: https://doi.org/10.1111/jdi.14366
[4] Kido N, Asahara SI. Recent advances in pancreatic β-cell dysfunction in type 2 diabetes mellitus: Intracellular stress and dedifferentiation. J Diabetes Investig. 2026 Aug;17(8):1254-1256. DOI: https://doi.org/10.1111/jdi.70357
[5] Dahiya R, Singh AP, Rawat A. Immunometabolic reprogramming and β-cell dedifferentiation: Integrated mechanisms driving type 2 diabetes progression. Diabetes Res Clin Pract. 2026 Feb;232:113111. DOI: https://doi.org/10.1016/j.diabres.2026.113111
[6] Van Tienhoven R, O'Meally D, Scott TA, Morris KV, Williams JC, Kaddis JS, Zaldumbide A, Roep BO. Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay. Cell. 2025 May 1;188(9):2407-2416.e9. DOI: https://doi.org/10.1016/j.cell.2025.02.018
[7] Yan Baiyi, Yao Lihua. Research Progress on the Damage of Pancreatic β-Cell Function Caused by Glycolipid Toxicity [J]. Journal of Jiangxi Science and Technology Normal University, 2022, (6): 71-74.
[8] Barinova AA, Bogomolova AY, Bogomazova AN, Borisova AA, Kiselev SL, Panova AV. Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes. Int J Mol Sci. 2025 Sep 8;26(17):8749.
[9] Wang C, Wu Y, Jiang J. The role and mechanism of mesenchymal stem cells in immunomodulation of type 1 diabetes mellitus and its complications: recent research progress and challenges: a review. Stem Cell Res Ther. 2025 Jun 17;16(1):308. DOI: https://doi.org/10.1186/s13287-025-04431-1
[10] Wang K, Li J, Han C, Li J. Mechanisms and Drug-Augmenting Strategies of Mesenchymal Stem Cells for Preserving β-Cell in Type 2 Diabetes. Drug Des Devel Ther. 2026 Apr 22;20:586404. DOI: https://doi.org/10.2147/DDDT.S586404
[11] Progress in stem cell therapy for type 1 diabetes.2026. https://www.eurekalert.org/news-releases/1123903#1
[12] Bi, H., Ma, R., Chen, Z. et al. Enhanced stem cell-derived pancreatic β cell production through mitochondrial metabolic reprogramming improves islet cell therapy for diabetes. Cell Commun Signal .2026. DOI: https://doi.org/10.1186/s12964-026-03169-4
[13] Tan, V.M., Anh, K.T.L., Hien, L.T.D. et al. Evaluating iPSC-based interventions for diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr 18, 157 (2026). https://doi.org/10.1186/s13098-026-02168-2 DOI: https://doi.org/10.1186/s13098-026-02168-2
[14] Barinova AA, Bogomolova AY, Bogomazova AN, Borisova AA, Kiselev SL, Panova AV. Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes. Int J Mol Sci. 2025 Sep 8;26(17):8749. DOI: https://doi.org/10.3390/ijms26178749
[15] Koishybayeva D, Amirashov A, Balmagambetova S, Mussin NM, Tamadon A. Mesenchymal stem cell therapy for diabetes: An umbrella review. Tissue Cell. 2025 Oct;96:103043. DOI: https://doi.org/10.1016/j.tice.2025.103043
[16] Chen Chunlan, Ye Meiyi, Pan Yewei, et al. The immunomodulatory effect of umbilical cord mesenchymal stem cells on type 2 diabetes [J]. Chinese Journal of Tissue Engineering Research, 2025, 29(23): 5031-5040.
[17] Shi Y, Feng Y, Li T, Wu J, Ling Q, Guo M, Fu T, Nie T, Ji J, Meng X, Liao H, Xu J, Wei T, Huang D, Zhou Y, Mou X, Xu X, Dong J, He D, Zhao Y, Zhou X, Dai H, Ni Z, Wang X, Wang Y, Fu Z, Ding G, Dong W, Li X, Yang T, Jia W, Li S, Zhang M, Shapiro AMJ, Cheng X, Yin H. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant. Lancet Diabetes Endocrinol. 2026 Apr;14(4):285-288.
[18] The Shanghai team has solved a global problem! The transplantation of regenerated pancreatic islets offers diabetes patients the hope of being free from insulin injections. https://www.sibcb.ac.cn/iptto/news.jsp?ID=1543
[19] Lin TM, Lin TC, Lin CH, Lin CS. Overview of the major clinical trials investigating stem cells-based therapies for diabetes. Diabetes Metab. 2026 Mar;52(2):101738. DOI: https://doi.org/10.1016/j.diabet.2026.101738
[20] Shi Y, Feng Y, Li T, Wu J, Ling Q, Guo M, Fu T, Nie T, Ji J, Meng X, Liao H, Xu J, Wei T, Huang D, Zhou Y, Mou X, Xu X, Dong J, He D, Zhao Y, Zhou X, Dai H, Ni Z, Wang X, Wang Y, Fu Z, Ding G, Dong W, Li X, Yang T, Jia W, Li S, Zhang M, Shapiro AMJ, Cheng X, Yin H. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant. Lancet Diabetes Endocrinol. 2026 Apr;14(4):285-288. DOI: https://doi.org/10.1016/S2213-8587(25)00423-1
[21] Abolhasani, S., Ahmadi, Y. & Jalizih, A. Emerging molecular and cellular therapeutics for type 2 diabetes: integrating stem cell and miRNA approaches toward precision medicine. Stem Cell Res Ther (2026). https://doi.org/10.1186/s13287-026-05202-2 DOI: https://doi.org/10.1186/s13287-026-05202-2
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

